Purulent Hydradenitis. Part II

Cover Page
  • Authors: Rodionov A.N.1, Sobolev A.V.2, Skrek S.V.1,3, Wolkenstein P.4, Yunovidova A.A.3
  • Affiliations:
    1. North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation
    2. Research Institute of Medical Mycology named after P. N. Kashkin of the North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation
    3. The Pierre Wolkenstein French Dermatological Clinic
    4. Dermatological Service of the Henri Mondor University Hospital
  • Issue: Vol 93, No 6 (2017)
  • Pages: 41-46
  • Section: LITERATURE REVIEW
  • URL: http://vestnikdv.ru/jour/article/view/351
  • DOI: https://doi.org/10.25208/0042-4609-2017-93-6-41-46

Abstract


Purulent hydradenitis is a chronic relapsing disease that affects 4% of the population, caused by uncontrolled growth of hair follicle and apocrine gland cells, which leads to the development of autoimmune and then septic inflammation. The provoking factors are obesity, smoking, formation of apocrine glands in the body. The variety of subordinates of Suppurative hydradenitis, differences in the prognosis and course of the disease, as well as the need to manage patients with this pathology in the surgical department, determine the standardization of the therapeutic algorithm and the objectification of the degree of clinical response to the therapy using scoring scales.

About the authors

A. N. Rodionov

North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation

Author for correspondence.
Email: fake@neicon.ru

Russian Federation

д.м.н., профессор кафедры дерматовенерологии 

A. V. Sobolev

Research Institute of Medical Mycology named after P. N. Kashkin of the North-Western State Medical University
named after I. I. Mechnikov, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Russian Federation

д.м.н., профессор кафедры 

S. V. Skrek

North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation ;
The Pierre Wolkenstein French Dermatological Clinic

Email: fake@neicon.ru

Russian Federation

к.м.н., ассистент кафедры дерматовенерологии 

P. Wolkenstein

Dermatological Service of the Henri Mondor University Hospital

Email: fake@neicon.ru

France

заведующий кафедрой, Дерматологическая служба университетского госпиталя Энри Мондор

A. A. Yunovidova

The Pierre Wolkenstein French Dermatological Clinic

Email: anastasia.yunovidova@gmail.com

Russian Federation

врач-дерматовенеролог Клиники кожных болезней Пьера Волькенштейна

 

References

  1. Kurzen H., Kurokawa I., Jemec G. B. et al. What Causes Hidradenitis Suppurativa? Exp. Dermatol. 2008;17(5):455–456.
  2. Jemec G. B. The Symptomatology of Hidradenitis Suppurativa in Women. Br. J. Dermatol. 1988;119(3):345–350.
  3. Melnik B. C., Plewig G. Impaired Notch-MKP-1 Signalling in Hidradenitis Suppurativa: an Approach to Pathogenesis by Evidence from Translational Biology. Exp. Dermatol. 2013;22(3):172–177.
  4. Zouboulis C. C., Desai N., Emtestam L. et al. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa. J. Eur. Acad. Dermatol. Venereol. 2015;29(4):619–644.
  5. Canoui-Poitrine F., Le Thuaut A., Revuz J. E. et al. Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. J. Invest. Dermatol. 2013;133(6):1506–1511.
  6. Poli F., Wolkenstein P., Revuz J. Back and Face Involvement in Hidradenitis Suppurativa. Dermatology. 2010;221(2):137–141.
  7. Canoui-Poitrine F., Revuz J. E., Wolkenstein P. et al. Clinical Characteristics of a Series of 302 French Patients with Hidradenitis Suppurativa, with an Analysis of Factors Associated with Disease Severity. J. Am. Acad. Dermatol. 2009;61(1):51–57.
  8. Sartorius K., Lapins J., Emtestam L., Jemec G. B. Suggestions for Uniform Outcome Variables when Reporting Treatment Effects in Hidradenitis Suppurativa. Br. J. Dermatol. 2003;149(1):211–213.
  9. Freysz M., Jemec G. B., Lipsker D. A Systematic Review of Terms Used to Describe Hidradenitis Suppurativa. Br. J. Dermatol. 2015;173(5):1298–1300.
  10. Kimball A. B., Kerdel F., Adams D. et al. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa: a Parallel Randomized Trial. Ann. Intern. Med. 2012;157(12):846–855.
  11. Grant A., Gonzalez T., Montgomery M. O. et al. Infliximab Therapy for Patients with Moderate to Severe Hidradenitis Suppurativa: a Randomized,

Statistics

Views

Abstract - 241

PDF (Russian) - 97

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies